SCHEMBL738036

SCHEMBL738036

C[C]c1cccc(C(F)(F)F)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.54
MAPK1 P28482 1/20 0.54
GRM5 P41594 4/20 0.47
CES2 O00748 1/20 0.44
MGLL Q99685 1/20 0.44
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
HTR2B P41595 1/20 0.43
FFAR1 O14842 1/20 0.43
PTPN1 P18031 1/20 0.43
ALDH1A1 P00352 1/20 0.42
NFE2L2 Q16236 1/20 0.42
TAAR1 Q96RJ0 1/20 0.41
MAOB P27338 2/20 0.41
MIF P14174 1/20 0.41
HTR3E A5X5Y0 1/20 0.40
HTR3B O95264 1/20 0.40
HTR3A P46098 1/20 0.40
HTR3D Q70Z44 1/20 0.40
HTR3C Q8WXA8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8006286 0.83 GRM5 (0.53) TSHRMAPK1GRM5CES2MGLL
SCHEMBL2273427 0.82 TSHR (0.52) TSHRMAPK1GRM5CES2MGLL
SCHEMBL30873473 0.82 GRM5 (0.58) TSHRMAPK1GRM5CES2MGLL
SCHEMBL381220 0.81 TSHR (0.47) TSHRMAPK1GRM5CES2MGLL
SCHEMBL440276 0.78 KIF11 (0.50) TSHRMAPK1GRM5CES2
SCHEMBL933875 0.78 PTPN1 (0.61) TSHRMAPK1GRM5CES2MGLL
SCHEMBL1858907 0.78 TSHR (0.48) TSHRMAPK1GRM5CES2MGLL
SCHEMBL695156 0.78 TSHR (0.48) TSHRMAPK1GRM5CES2MGLL
SCHEMBL97979 0.78 CES2 (0.48) TSHRMAPK1GRM5CES2MGLL
SCHEMBL195567 0.78 MIF (0.49) TSHRMAPK1GRM5CES2MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010025870-A1 SYNERGISTIC COMBINATIONS OF THIADIAZOL CARBONIC ACID DERIVATIVES BAYER CROPSCIENCE AG (DE) 2010-03-11 WO claimed
US-20140343092-A1 Pyrrolopyridinone Compounds And Methods For Treating HIV VIIV HEALTHCARE UK LIMITED (GB) 2014-11-20 US disclosed
EP-2802210-A1 FUNGICIDE COMPOSITIONS COMPRISING FLUOPYRAM, AT LEAST ONE SUCCINATE DEHYDROGENASE (SDH) INHIBITOR AND OPTIONALLY AT LEAST ONE TRIAZOLE FUNGICIDE Bayer Intellectual Property GmbH (DE) 2014-11-19 EP disclosed
EP-1498411-B9 DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO (JP) 2013-12-04 EP disclosed
WO-2013104609-A1 FUNGICIDE COMPOSITIONS COMPRISING FLUOPYRAM, AT LEAST ONE SUCCINATE DEHYDROGENASE (SDH) INHIBITOR AND OPTIONALLY AT LEAST ONE TRIAZOLE FUNGICIDE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-07-18 WO disclosed
EP-1498411-B1 DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO (JP) 2013-01-16 EP disclosed
US-8138182-B2 Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2012-03-20 US disclosed
US-20100087442-A1 DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD (JP) 2010-04-08 US disclosed
US-7655804-B2 N-[(1S)-3-{(2Z)-2-[(4R)-3,4-dimethyl-1,3-thiazolidin-2-ylidene]hydrazino}-2,3-dioxo-1-(tetrahydro-2H-pyran-4-yl)propyl]cycloheptanecarboxamide; cysteine protease inhibitors; for the treatment of inflammatory, immune, ischemic, respiratory,circulatory, neuronal, blood, hepatic and metabolic diseases ONO PHARMACEUTICAL CO., LTD. (JP) 2010-02-02 US disclosed
US-20060111303-A1 Diketohydrazine derivative compounds and drugs contaiing the compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2006-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087442-A1 DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT SERPINB1, CTSZ, ELANE TSHR 4219/4885MAPK1 1216/4885GRM5 692/4885
US-20140343092-A1 Pyrrolopyridinone Compounds And Methods For Treating HIV DHPS, PRNP, TYMP TSHR 4708/4885MAPK1 3143/4885GRM5 1401/4885
US-20060111303-A1 Diketohydrazine derivative compounds and drugs contaiing the compounds as the active ingredient SERPINB1, CTSZ, SERPINE1 TSHR 4124/4885MAPK1 1173/4885GRM5 1456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.